Anna Kovalskaya

Dr. Anna Kovalskaya


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2022 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
AKAnna Kovalskaya
Anna Kovalskaya
GBG. R. Bikbaeva
G. R. Bikbaeva
Dmitry V. DuplyakovDmitry V. Duplyakov
Dmitry V. Duplyakov
Aim. To study the effect of high-dose combined lipid-lowering therapy (statins + ezetimibe vs statins + PCSK9 inhibitors) on plaque vulnerability assessed using multimodal imaging (coronary computed tomography angiography (CCTA) and optical coherence tomography, as well as biomarkers in patients with acute coronary syndrome (ACS).Material and methods. This open, prospective, randomized, single-center study will include 120 patients admitted urgently with an ACS. All patients will undergo percutaneous coronary intervention of the infarct-related artery, as well as intracoronary imaging using optical coherence tomography of one or two noninfarct-related arteries. During hospitalization, patients will receive standard therapy for ACS according to clinical guidelines, while statins will initially be prescribed at a maximum dosage of atorvastatin 80 mg/rosuvastatin 40 mg.Patients who showed high compliance and did not reach the target low-density lipoprotein cholesterol (LDL-C) values (≤1,4 mmol/l) 1 month after myocardial infarction/unstable angina at the second visit will be randomized into two groups. Patients of group 1 will receive PCSK9 inhibitors (alirocumab 150 mg by subcutaneous injection once every 2 weeks or evolocumab 140 mg by subcutaneous injection once every 2 weeks) in addition to maximum statin therapy (atorvastatin 80 mg/rosuvastatin 40 mg), while group 2 participants will take ezetimibe at a dose of 10 mg in combination with the maximum dose of statins. In addition, at the second visit, patients will undergo CCTA, assess the cardio-ankle vascular index (CAVI) index and laboratory tests (complete blood count (neutrophil-to-lymphocyte ratio NLR), lipid profile, alanine aminotransferase (ALT), aspartate aminotransferase (AST), Troponin I, Galectin-3, high-sensitivity C-reactive protein (hs-CRP), metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinase 1 (TIMP-1), neutrophil gelatinase-associated lipocalin (NGAL). Total follow-up will last 52 weeks. At the final visit, patients will undergo CCTA, assessment of the CAVI index and laboratory status (NLR, lipid profile, ALT, AST), Troponin I, Galectin-3, hs-CRP, MMP-9, TIMP-1, NGAL).Primary endpoint: reduction in plaque vulnerability according CCTA in non-infarct-related coronary arteries Secondary endpoints: death, stent thrombosis/restenosis, non-fatal myocardial infarction, readmissions with progressive angina, repeat revascularization; changes of the lipid profile (total cholesterol, LDL-C, high-density lipoprotein cholesterol, triglycerides) against the background of maximum combination therapy with statin + PCSK9 inhibitors or statin + ezetimibe; changes of the biomarkers of cardiac injury (Troponin I), inflammation (NLR, hs-CRP, NGAL, Galectin-3) and matrix remodeling (MMP-9, TIMP-1).Conclusion. Our study will allow for the first time to compare and evaluate the effect of both PCSK9 inhibitors and ezetimibe in combination with high-dose statin therapy on reducing the plaque vulnerability according to CCTA in non-infarction-related coronary arteries in patients with ACS undergoing percutaneous coronary intervention, as well as to evaluate the diagnostic value of inflammatory biomarkers (NLR, hs-CRP, NGAL, Galectin-3) and matrix remodeling (MMP-9, TIMP-1).

27 July 2023 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
AKAnna Kovalskaya
Anna Kovalskaya
Dmitry V. DuplyakovDmitry V. Duplyakov
Dmitry V. Duplyakov
Aim. To study the role of biomarkers in assessing the vulnerability of atherosclerotic plaques.Material and methods. A review of literature sources investigating the biomarker assessment of the vulnerability of atherosclerotic plaques published for the period 01.01.2016 to 31.12.2022 was carried out. Literature search was carried out in English and Russian in PubMed databases, in Google Academy, Elibrary.ru according to the following keywords: “biomarkers of plaque vulnerability”, “NLR and vulnerable plaque”, “CRP and vulnerable plaque”, ”MMP-9 and vulnerable plaque”, “TIMP-1 and vulnerable plaque”, ”galectin-3 and vulnerable plaque”, “NGAL and vulnerable plaque”. A total of 183 articles were found, of which 42 articles in full-text format containing original clinical studies were selected for the preparation of this review.Results. Numerous studies have shown that the vulnerability and rupture of the plaque, rather than its size and severity of stenosis, are the main cause of cardiovascular events in patients with coronary heart disease. Small plaques rich in lipids often become unstable due to an inflammatory reaction supported by the interaction between lipoproteins, monocytes, macrophages, T-lymphocytes and vascular wall cells. NLR, CRP, NGAL, Galectin-3, as well as markers of extracellular matrix degradation (MMP-9, TIMP-1) can play a special role in assessing the vulnerability of plaques.Conclusion. The development of acute coronary syndrome is based on the destabilization of the atherosclerotic plaque, which occurs not only due to changes in its lipid composition, but also infiltration by immuno-inflammatory cells, degradation of the extracellular matrix, as well as an active inflammatory reaction and neovascularization of the plaque. Therefore, traditional imaging methods that characterize the plaque by its appearance and size are not enough to predict the risk of rupture and the development of an acute thrombotic event. Thus, there is a need to identify new biomarkers that would correlate with the instability of plaque atheroma.

13 August 2024 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
GBG. R. Bikbaeva
G. R. Bikbaeva
AKAnna Kovalskaya
Anna Kovalskaya
KKK. V. Kuznetsova
K. V. Kuznetsova
TPT. V. Pavlova
T. V. Pavlova
Dmitry V. DuplyakovDmitry V. Duplyakov
Dmitry V. Duplyakov
The aim was to evaluate the potential of various imaging methods in the diagnosis of vulnerable coronary plaques and their stabilization using various lipid-lowering therapy regimens.The sources were searched in the PubMed database using the following keywords: "vulnerable (unstable) plaque" AND "PCSK9 inhibitors" AND "intravascular ultrasound" OR "optical coherence tomography" OR "computed tomography angiography". As a result, 8 original clinical trials were selected that corresponded to the review purpose. We assessed the results of following studies on plaque imaging and their regression with various lipid-lowering therapy regimens: GLAGVO, ODYSSEY J, PACMAN-AMI, HUYGENS, ALTAIR, ARCHITECT, etc. The results of most studies have established the advantages of a combined regimen of lipid-lowering therapy (statin+PCSK9 inhibitor) in reducing the rate of cardiovascular events in com­parison with statin monotherapy. The reduction in plaque volume ranged from 0,95% to 2,13% in patients receiving a combination of lipid-lowering drugs, while in monotherapy, it increased from 0,05% to 0,92% (GLAGOV, PACMAN-AMI). The changes of minimum fibrous cap thickness varied from 18,0-62,67 µm with combined therapy and 13,2-33,19 µm with monotherapy (PACMAN-AMI, Gao F). Lipid arc regression was 57,5о in combination therapy (statin+PCSK9 inhibitor) and 31,4о in statin monotherapy (HUYGENS). Imaging diagnostic methods makes it possible to identify vulnerable plaques, which helps in consideration of combination lipid-lowering therapy. In addition, plaque visualization makes it possible to evaluate the treatment effectiveness.

19 September 2024 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
AKAnna Kovalskaya
Anna Kovalskaya
GBG. R. Bikbaeva
G. R. Bikbaeva
Dmitry V. DuplyakovDmitry V. Duplyakov
Dmitry V. Duplyakov
ЕСЕкатерина Савинова
Екатерина Савинова
Aim. To assess the relationship between simple inflammation markers and plaque vulnerability criteria according to coronary computed tomography angiography (CCTA), as well as lipid profile parameters in patients with acute coronary syndrome (ACS).Material and methods. This prospective, randomized, single-center study included 125 patients admitted urgently with the clinical performance of ACS (myocardial infarction (MI) — 94 patients; unstable angina (UA) — 31). All patients underwent percutaneous coronary intervention of the infarct-related artery. In addition, all patients had atherosclerotic plaques with stenosis <50% in one or two non-infarct-related arteries. Treatment of ACS was carried out according to the guidelines. One month after ACS, all patients underwent CCTA to detect vulnerable plaques, as well as lipid profile analysis (total cholesterol (TC), lowdensity lipoprotein (LDL) cholesterol, triglycerides, high-density lipoprotein (HDL) cholesterol), simple inflammatory biomarkers C-reactive protein (CRP), neutrophilto-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-HDL-C ratio (MHR), lymphocyte-to-monocyte ratio (LMR), lymphocyte-to-CRP ratio (LCR).Results. Of the 125 patients included in the study, MI was diagnosed in 94 (75%) patients, and UA in the remaining cases. In the acute period, in patients with MI, the HDL-C value was significantly lower 1,2 (1,03; 1,5) mmol/L than in the group of patients with UA (1,4 (1,24; 1,58) mmol/L), p=0,044. NLR was higher in patients with MI — 2,96 (2,09; 3,99) versus 2,21 (1,69; 2,71) in the UA group (p=0,018). One month after the index event, the HDL-C level remained significantly lower in the MI group 1,08 (0,95; 1,34) mmol/L, and the MHR was higher (0,52 (0,37; 0,64)) than in UA (1,25 (1,15; 1,34) mmol/L and 0,41 (0,31; 0,52)), respectively. The LCR after 1 month was almost 2 times higher in the UA group — 1,32 (0,65; 2,28) versus 0,66 (0,34; 1,28) in the MI group (p=0,028). The vulnerability criteria of plaques according to CCTA data were identified in 55 (44%) patients in the general group with ACS, of which positive remodeling was detected in 35 patients, a low-density area — in 30, and punctate calcifications (PC) — in 11. Patients in the general ACS group were divided by vulnerability criteria. Patients with PC had a significantly (p=0,004) higher level of HDL-C 1,22 (1,02; 1,34), compared to those without it 0,97 (0,77; 1,13). The MHR was higher (p=0,024) in the presence of PC (0,61 (0,48; 0,86)) than without it (0,46 (0,35; 0,63)). No significant differences were found for other indicators. When conducting the ROC analysis in patients with PC, the threshold level of HDL-C was 0,98 (AUC: 0,76, Sensitivity 66,7%, Specificity 77,4%), the threshold level of HDL-C in the presence of low-density area simultaneously with PC was also 0,98 (AUC: 0,83, Sensitivity 75%, Specificity 75,7%).Conclusion. The HDL-C and MHR indicators significantly changed in patients who had ACS and microcalcifications in the plaques.

29 May 2024 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
AKAnna Kovalskaya
Anna Kovalskaya
Dmitry V. DuplyakovDmitry V. Duplyakov
Dmitry V. Duplyakov
AKA. P. Kuritsyna
A. P. Kuritsyna
LLL. V. Limareva
L. V. Limareva
Aim. To evaluate the relationship between markers of inflammation and matrix remodeling and criteria for a vulnerable plaque according to multislice computed tomography (MSCT) coronary angiography, as well as lipid profile parameters in patients with acute coronary syndrome (ACS).Material and methods. This prospective single-center study included 125 patients admitted urgently with ACS. All patients underwent percutaneous coronary intervention of the infarct-related artery. In ad­dition, in all patients, there were plaques in one or two non-infarct-related arteries with stenosis 34,0 (8,6; 61,0) vs 5,9 (2,8; 25,4) ng/ml in the group with PCs (p=0,046). The regression model including the MMP-9, TIMP-1, NGAL, Gal-3 in identifying vulnerable plaques was found to be significant (p<0,001).Conclusion. Criteria for vulnerable plaque in patients after ACS have a significant relationship with markers of inflammation and matrix remo­deling.

15 July 2025 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
GBG. R. Bikbaeva
G. R. Bikbaeva
AKAnna Kovalskaya
Anna Kovalskaya
KKK. V. Kuznetsova
K. V. Kuznetsova
PDP. D. Duplyakova
P. D. Duplyakova
ATA. A. Tukhbatova
A. A. Tukhbatova
ЕСЕкатерина Савинова
Екатерина Савинова
Aim. To assess the detection rate of vulnerable plaques using computed tomography (CT) in patients after acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI).Material and methods. The study included 125 patients with ACS who underwent PCI (men, 68%; median age, 59 (51-66) years). One month after the index event, patients who did not achieve target low-density lipoprotein cholesterol values were divided into two groups depending on the signs of vulnerable plaques according to CT data.Results. Vulnerable plaques were detected in 56 (44,8%) patients using CT (69,6% men, median age 60 (51-63) years). Patients with vulnerable plaques were more likely to have right coronary artery (CA) involvement — 53,6 vs 11,6% (p<0,001); left main CA — 33,9 vs 5,8% (p<0,001); left anterior descending artery — 76,8 vs 15,9% (p<0,001); circumflex artery — 48,2 vs 18,8% (p<0,001) compared to patients without vulnerable plaques. The coronary calcium index in patients with vulnerable plaques was significantly higher — 111 (29-247) vs 35 (1-138) (p=0,003). Patients with signs of vulnerable plaques had more severe coronary artery disease according to the segment-stenosis (SSS) and segment-involvement (SIS) scores — 3 (1-4) vs 0 (0-1) (p<0,001) compared to patients without vulnerable plaques.Conclusion. The detection rate of vulnerable plaques in patients after ACS and PCI not achieved target LDL values while receiving highdose statin therapy was 44,8%. Patients with vulnerable plaques were characterized by more spread atherosclerotic coronary involvement and a high calcium index.